focus -WSS

focus

author：Wikipedia 2025-10-01 04:14:07 - browse：7452

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Positive childhood experiences can help future health

focus

WSS

How AI can help patients find reliable information about doctors

Physicians and social media: If you see something, say something?

Roche drug slashes death risk in early

STAT Summit: The economic case for universal basic health care

App could help diagnose ear infections more accurately — and at home

Gene editing the human germline: What are the risks?

Wikipedia

focus

focus

Walensky prepares to leave CDC — and Congress — behind

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

ChatGPT in medicine: STAT answers readers' burning questions

Stop the failed accountable care organization experiment

Activists slam private health insurers over coverage restrictions

Leading voice in opioid treatment defends methadone clinic system

Guidelines to prevent youth baseball injuries need more muscle

Readout LOUD podcast: Live from the 2023 STAT Summit

Anesthesiologist group: stop taking Ozempic before surgery

Roche drug slashes death risk in early

hotspot

Argenx readies a blockbuster opportunity with drug for autoimmune disease

How AI can help patients find reliable information about doctors

Orchard's therapy for neuron disease in children wins FDA approval

Smaller biotechs seek to piggyback on weight loss drug boom

Intermittent fasting comes with a heart risk? Not so fast

Colonoscopy prep: Liquid

focus

focus

focus

explore